Erythrocyte electron transport system activity in COPD: metabolic changes and disease progression

<bold>Aim:</bold> To study the metabolic activity of erythrocytes in patients with COPD at different stages. Materials and methods: 150 patients with COPD severity and disease duration from 3 to 15 years were examined. The average age of the patients was 47±1.5 years. Patients were divided into 3 groups (Gr): Gr 1 included 54 patients with COPD stage 1, Gr 2-59 with COPD stage 2, and Gr 3 comprised 37 with COPD stage 3. The control group included 40 (CG). The diagnosis of COPD and its severity were verified based on the GOLD 2024 criteria. The activity of electron transport enzymes in erythrocytes was measured by cytochromes C, b5, and NADH-cytochrome b5 reductase levels. <bold>Results:</bold> The study revealed a significant decrease in erythrocyte cytochrome C levels in patients with progressive COPD. In the CG, this parameter was 6.41±0.21 nmol/Hb; in Gr 2, it ↓ was a 4.48±0.11 nmol/Hb (30.1%) reduction compared to the CG. In Gr 3, the cytochrome C level (⭣34.5%, p<0.001) to 4.2±0.14 nmol/Hb. NADH-cytochrome b5 reductase activity in the CG level was 63.21±1.97 nmol/min/Hb (↑25.1%, p<0.001). In Gr 1, enzyme activity increased to 20.5% higher than the CG (p<0.001). In Gr 2, the parameter reached 78.96±2.12 nmol/min/Hb, reflecting a 24.9%. In Gr 3, enzyme activity rises to 79.09±2.59 nmol/min/Hb (p<0.001). <bold>Conclusion:</bold> Pronounced alterations in erythrocyte electron transport system enzyme activity in patients with COPD indicate progressive metabolic disturbances leading to erythrocyte dysfunction. The obtained data confirm the importance of assessing erythrocyte electron transport system activity in the pathogenesis and prognosis of COPD.

Ҳали таржима қилинмаган